To test the functional consequence of Hsp90 inhibition on anti-tumour immunity, we used the MC38 mouse colorectal cancer (CRC) model with variants made to resemble two clinically relevant subtypes. This evidence concerns the gene HSP90AB1 and colorectal carcinoma.